Post-earnings recap
Reported
Mon, Nov 8, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Krystal Biotech is still in a developmental phase, with no revenue reported and a significant loss per share. The stock's decline of 4.33% suggests that investors are reacting negatively to the lack of guidance and clarity on future performance. The company’s focus on R&D may be promising, but without concrete financial metrics, investor confidence may wane.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | +6.67% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their pipeline but did not offer specific insights into future performance. The lack of guidance may contribute to investor uncertainty.
Management did not provide specific revenue figures or future guidance.
The company emphasized ongoing research and development efforts.